11.07.01ae, Hematopoietic Stem Cell Transplantation
Summary
Independence Blue Cross is revising its Hematopoietic Stem Cell Transplantation policy effective 02/01/2027. Key changes include reclassifying tandem autologous transplantation for Hodgkin Lymphoma as experimental, removing Durie-Salmon staging criteria from Multiple Myeloma coverage, expanding Omisirge eligibility, removing G-CSF products from this policy (they move to primary drug policies), and removing five G-CSF-related HCPCS codes from coverage under this policy.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.